AMGN34:BVMF
Amgen Inc. BDR
75,52 R$
0,00%
(0,00) 1 d.
2. okt., 16:56:00 GMT-3 · BRL
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: AMGN34…
Atvērt
75,76 R$
Augsta
75,82 R$
Zema
75,32 R$
Tirgus kapitalizācija
217,90 mljrd.
Vid. apjoms
376,00
Apjoms
112,00
Augstākā 52 ned.
83,06 R$
Zemākā 52 ned.
47,76 R$
Apgrozībā esošās akcijas
540,63 milj.
Darbinieku skaits
32 tūkst.
Atvērt
75,76 R$
Augsta
75,82 R$
Zema
75,32 R$
Tirgus kapitalizācija
217,90 mljrd.
Vid. apjoms
376,00
Apjoms
112,00
Augstākā 52 ned.
83,06 R$
Zemākā 52 ned.
47,76 R$
Apgrozībā esošās akcijas
540,63 milj.
Darbinieku skaits
32 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
The Motley Fool
·
pirms 6 stundām
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
MarketWatch
·
pirms 2 dienām
Amgen Inc. stock underperforms Friday when compared to competitors
GuruFocus
·
pirms 3 dienām
Amgen Inc (AMGN) Shares Fall 3.4% -- GF Value Says Still Overval
Yahoo Finance
·
pirms 3 dienām
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Profils
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
Par “Amgen Inc. BDR”
ĢenerāldirektorsRobert A. Bradway
Darbinieki31,5 tūkst.
Dibināšanas datums1980
Galvenais birojsTauzandoksa, Kalifornija, Amerikas Savienotās Valstis
Sektors-
Tīmekļa vietneamgen.com